MELBOURNE, Australia, May 10, 2022 (GLOBE NEWSWIRE) — Opthea Limited (OPTOPTa clinical-stage biopharmaceutical company developing novel therapies to treat widespread and progressive retinal diseases, announces a presentation at the upcoming Retina World Congress 2022, to be held in Fort Lauderdale, Florida, May 12-15, 2022.
Dr. David Boyer, MD, will present the OPT-302 combination therapy in wet AMD, focusing on the Phase 3 program designed to evaluate the superiority of medium BCVA over anti-VEGF-A monotherapy.
The details of the podium oral presentation are as follows:
Presentation title: OPT-302 as an adjunct to anti-VEGF therapy
Session: Macular degeneration
Presenter: David Boyer, MD, Assistant Clinical Professor, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Senior Associate, Retina-Vitreous Associates Medical Group, Beverley Hills, CA
Date and time: May 13, 2022 from 4:36 p.m. to 4:42 p.m. ET
The World Retina Congress has established itself as one of the world’s leading meetings focused on retinal health, providing scientific, educational and professional forums led by international thought leaders and pioneering retinal specialists .
About Opthea Limited
Opthea (OPTOPT is a biopharmaceutical company that develops new therapies to address the unmet need in the treatment of widespread and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s lead product candidate, OPT-302, is in pivotal Phase 3 clinical trials and is being developed for use in combination with anti-VEGF-A monotherapies to achieve broader inhibition of the VEGF family, with the aim of improving overall efficacy and demonstrating superior vision gains over that which can be achieved by inhibiting VEGF-A alone.
Risks inherent in investing in biotechnology companies
There are a number of inherent risks associated with the development of pharmaceutical products to a marketable stage. The lengthy clinical trial process is designed to assess the safety and effectiveness of a drug before it is marketed, and a significant proportion of drugs fail one or both of these criteria. Other risks include uncertainty of patent protection and proprietary rights, whether patent applications and issued patents will provide adequate protection to enable product development, obtaining necessary approvals from drug regulatory authorities and the difficulties caused by rapid advances in technology. Companies like Opthea are dependent on the success of their research and development projects and their ability to attract funding to support these activities. Investments in research and development projects cannot be evaluated on the same basis as commercial and manufacturing enterprises. Therefore, investing in drug development companies should be considered highly speculative. Opthea strongly recommends seeking professional investment advice before making such investments.
Cleared for broadcast on ASX by Megan Baldwin, CEO and Managing Director
|Business and Media Inquiries:|
|United States and International:||Australia:|
|Sam Martin||Rudi Michelson|
|Slang Partners||Monsoon Communications|
|Tel: +1 212-600-1902||Tel: +61 (0) 3 9620 3333|
|Silvana Guerci Lena|
|NorthStream Global Partners|
|Tel: +1 973-509-4671|
|Join our email database to receive program updates:|
|Tel: +61 (0) 3 9826 0399 Email: [email protected] Web: www.opthea.com|